Haim Bio Co., Ltd.   Report issue

For profit Phase 1
Founded: Seoul Korea, Republic of (2011)

Organization Overview

First Clinical Trial
2019
NCT04262739
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Haim Bio Co., Ltd.

Active Ingredients

Drugs in Phase 1 Trials (2)

nyh100p (1 trial)

nyh817g (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2